NL-OMON34455已完成不适用
A randomized double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety and pharmacokinetics of OCR 002 in healthy volunteers. - OCR-002 SAD+MAD study in HV
Ocera Therapeutics0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male and female subjects
- •18 - 55 years of age
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS/ In case of participation in another drug study withing 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior to the start of this study.
研究者
相似试验
已完成
不适用
Evaluation of the effect of choline-stabilized orthosilicic acid on the symptoms of knee osteoarthritisMusculoskeletal DiseasesGonarthrosis [arthrosis of knee]Knee osteoarthritisISRCTN10096951Bio Minerals NV227
已完成
不适用
A randomized, double-blind, placebo-controlled single and multiple ascending dose study of the safety, tolerability and pharmacokinetics of oral doses of SAR443122 in healthy adult subjects.Auto immune disease10003816NL-OMON48479Sanofi-aventis97
终止
1 期
A First-In-Human study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of NT-0167 in Healthy Volunteers.InflammationInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12620000685910odThera41
已完成
不适用
phase I clinical trial to investigate the safety, tolerability, and pharmacokinetics of HY209 gel as an possible treatment option for atopic dermatitisDiseases of the skin and subcutaneous tissueKCT0003988Shaperon56
已完成
不适用
A randomized, double-blind, placebo-controlled single and multiple ascending dose study to test the safety, tolerability, pharmacokinetics and pharmacodynamics of NT-0167 in healthy volunteersinflammatory disorders and neurodegenerative diseasesinflammatory disordersneurodegenerative diseasesNL-OMON49667odThera80